CRISPR-Cas enzymes are increasingly entering clinical trials for gene therapies but can sometimes alter DNA off-target. We present an approach to modify the guide RNA to effectively eliminate off-target activity for target sequences of interest.
- Ashley Herring-Nicholas
- Hillary Dimig
- Eric A. Josephs